Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17972909 | 0.85 | — | — | |
| SCHEMBL29955111 | 0.74 | — | — | |
| SCHEMBL14594879 | 0.69 | — | — | |
| SCHEMBL3193277 | 0.69 | CES2 (0.47) | CES2CES1MGLLHDAC8HDAC6 | |
| SCHEMBL10956943 | 0.69 | CES2 (0.47) | CES2CES1MGLLHDAC8HDAC6 | |
| SCHEMBL3185717 | 0.69 | CES2 (0.47) | CES2CES1MGLLHDAC8HDAC6 | |
| SCHEMBL28366146 | 0.69 | — | — | |
| SCHEMBL7129291 | 0.67 | — | — | |
| SCHEMBL5659312 | 0.67 | — | — | |
| Boric Acid SCHEMBL11503478 | 0.67 | CES2 (0.52) | CES2CES1HDAC8HDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856734-B1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2025-09-24 | — | — | EP | disclosed |
| US-12065422-B2 | Reagents and process for direct C—H functionalization | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2024-08-20 | — | — | US | disclosed |
| US-20230227425-A1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2023-07-20 | — | — | US | disclosed |
| US-11608322-B2 | Reagents and process for direct C—H functionalization | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2023-03-21 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220002263-A1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2022-01-06 | — | — | US | disclosed |
| EP-3856734-A1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | Studiengesellschaft Kohle mbH (DE) | 2021-08-04 | — | — | EP | disclosed |
| EP-3650446-A1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | Studiengesellschaft Kohle mbH (DE) | 2020-05-13 | — | — | EP | disclosed |
| CN-108689989-B | DPP-4 inhibitor, preparation thereof and application thereof in diabetes | 张爱芳 | 2020-04-03 | — | — | CN | disclosed |
| CN-108675987-B | Quinoline derivative and application thereof in diabetes | 德州学院 | 2020-01-17 | — | — | CN | disclosed |
| US-20130157976-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | CLAUS ECKHARD (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20120252760-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | ZENTARIS GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| US-8217042-B2 | Pyridopyrazines and their use as modulators of kinases | ZENTARIS GMBH (DE) | 2012-07-10 | — | — | US | disclosed |
| EP-1957487-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | AEterna Zentaris GmbH (DE) | 2008-08-20 | — | — | EP | disclosed |
| US-20070149484-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | ZENTARIS GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
| WO-2007054556-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | ÆTERNA ZENTARIS GMBH (DE) | 2007-05-18 | — | — | WO | disclosed |
| EP-1785423-A1 | Pyridopyrazine derivatives and their use as kinase modulators | Zentaris GmbH (DE) | 2007-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149484-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | MAP4K2, MAP3K15, MAP3K5 | CES2 4284/4885CES1 4044/4885MGLL 4477/4885 |
| US-20230227425-A1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | CFH, DOHH, CTSH | CES2 232/4885CES1 1815/4885MGLL 2733/4885 |
| US-20220002263-A1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | CFH, DOHH, CTSH | CES2 232/4885CES1 1815/4885MGLL 2733/4885 |
| US-20120252760-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | MAP4K2, MAP3K15, MAP3K5 | CES2 4284/4885CES1 4044/4885MGLL 4477/4885 |
| US-11608322-B2 | Reagents and process for direct C—H functionalization | CFH, DOHH, CTSH | CES2 249/4885CES1 1828/4885MGLL 2912/4885 |
| US-20130157976-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | MAP4K2, MAP3K15, MAP3K5 | CES2 4284/4885CES1 4044/4885MGLL 4477/4885 |
| US-12065422-B2 | Reagents and process for direct C—H functionalization | CFH, DOHH, CTSH | CES2 249/4885CES1 1828/4885MGLL 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.